TransCelerate has unique attributes — leadership participation from the world’s leading biopharmaceutical organizations; Robust partnerships with industry organizations such as ACRO (Association of Clinical Research Organizations), CFAST (Coalition For Accelerating Standards and Therapies), CTTI (Clinical Trials Transformation Initiative) and SCRS (Society for Clinical Research Sites); and collaboration and insight from Global Regulatory Authorities — EMA (European Medicines Agency), FDA (U.S. Food and Drug Administration) and PMDA (Pharmaceuticals and Medical Devices Agency) — that enable us to create value for the industry.
We harness these attributes as we focus on five strategic priorities:
Improve the Site Investigator Experience as they work with Sponsors to execute Clinical Trials.
Facilitate the sharing of clinical trial related information as appropriate amongst industry stakeholders, focused on exchanges of information that would enable the industry to capture efficiencies.
Enable the industry to move toward greater harmonization of clinical trial processes to facilitate the advancement of technologies and processes within the broader clinical ecosystem.
Through collaboration, streamline redundant sponsor activities to reduce investigator and Patient burden, while refocusing resources to drive and deliver innovative drugs to patients faster and safely.
Improve the patient experience by decreasing patient burden, enabling a better informed patient and improving clinical research awareness, study participation and engagement.
** We will continue to evaluate our priorities as needed, and will take into consideration the changing industry landscape.